神经炎症PET和症状性阿尔茨海默病的长期认知和生存
相关实验视频
Updated: Jan 10, 2026

05:17
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
Published on: April 18, 2025
771
Roos M Rikken1,2,3, Maqsood Yaqub4,5, Emma M Coomans6,7
1Radiology & Nuclear Medicine, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, The Netherlands. r.rikken@amsterdamumc.nl.
Alzheimer's research & therapy
|November 22, 2025
概括
通过PK11195 PET测量的神经炎症,没有预测阿尔茨海默病患者的认知衰退或生存. 早期的神经炎症水平可能与长期AD结果没有直接关联.
科学领域:
- 神经成像是一种神经成像.
- 神经科学是一个神经科学.
- 阿尔茨海默氏症疾病研究研究
背景情况:
- 神经炎症与阿尔茨海默病 (AD) 的病理生理学有关.
- 神经炎症对阿尔茨海默病进展的确切贡献尚不清楚.
- 转位蛋白 (TSPO) 是神经炎症的标志物.
研究的目的:
- 为了研究神经炎症之间的关联,通过PK11195PET进行评估,以及AD和轻度认知障碍 (MCI) 患者的纵向认知衰退和生存.
- 测试假设,较高的[C]PK11195结合预测了更快的认知衰退和增加的死亡率.
主要方法:
- 利用了来自19名AD痴呆症患者,9名MCI患者和21名健康对照 (HC) 的PET数据.
- 采用主要成分分析 (PCA) 来识别神经炎症模式,并分析AD特定兴趣区域 (ROI) 的结合.
- 使用迷你精神状态检查 (MMSE) 评估纵向认知衰退,使用Cox比例危险模型评估生存数据.
主要成果:
- 在AD,MCI和HC组之间没有观察到PK11195PET结合的显著差异.
- 通过PCA或AD ROI分析的PK11195结合,没有预测MMSE纵向得分或MCI和AD参与者的生存率.
- 统计分析显示,神经炎症标志物对认知轨迹或死亡率没有显著的预测价值.
结论:
- 该研究没有发现证据表明[11C]PK11195PET结合可以预测AD或MCI患者的长期认知衰退或生存.
- 这些发现表明,通过PK11195PET测量的早期神经炎症可能不是长期疾病结果的直接决定因素.
- 需要进一步的研究来阐明神经炎症在阿尔茨海默病进展中的复杂作用.
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
772
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
772
![PET Imaging of Neuroinflammation Using [11C]DPA-713 in a Mouse Model of Ischemic Stroke](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F57243.jpg&w=3840&q=50)
